Biomolecular nmr assignments
Biomolecular nmr assignments from an existing patient with cancer (and similar tumors)When the researchers measured these nmr assignments, they noticed that they were much less frequent than those of normal cancer patients. The researchers further investigated the potential role of nmr binding in the treatment of the affected lesion.Conclusion.These studies may not directly support the concept of nmr binding as a major factor influencing cancer risk or may have limited applicability to cancer patients.
Also, because of the different types and intensities of the patient’s tumor, it is important that these studies remain open to interpretation due to the potential for bias.Conclusions.In light of the limited number of studies that have been conducted, the researchers should not allow readers of these blogs to assume that these findings are definitive, as more research is required to confirm the original findings of these studies, for example by the use of quantitative methods to examine all patient characteristics.
Such research also must establish the specific nature of cancer and its severity. Other methodological considerations, like the need to compare multiple studies, are also advisable when determining the extent of bias in an existing study.References.Dauphin M. K. & Mays H. B. (2001). Diagnosing an Alzheimers disease: an overview of the issue. J Cancer Epidemiol. , 2 , 311–316.Abbot S. & Fisk E.K. (2011). Diagnosing Cancer: The Roadmap for a Cancer Intervention. 2nd ed. London: Sage.Aden D. (1994).
The diagnosis and cure of cancer. New York: Guilford and Son.Amory J. (1995). The prognosis and treatment of lung cancer, Lancet, 36(1254), 593–600.Aulie M. A. & Jost F. H. (2002a, b). Clinical trials of lymphadenopathy therapy. Lancet, 366(1146), 866–882.Abdal Y. (2004). Cancer risk and metastases: a review. New York: Guilford and Son.Eddy J. (2013). Cancer risks and metastases: a review. Cancer J, 31(1), 103–117.Garris G. (2009, September 24, 2013). Cancer research, a review, and the next steps: the role of clinical and scientific methods.
American Journal of Cancer. , 107(4), 561–568.Greenstein J. L.